Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

Home health testing company SiPhox Health announced on Wednesday that it has raised $10 million in a seed financing round and $17 million in a Series A round.

AACC has announced that it is changing its name to the Association for Diagnostics & Laboratory Medicine (ADLM).

On 5 July 2023, National Medical Products Administration announced the imported Class I medical device product in June 2023. A total of 145 product information, including 7 products in the IVD industry, were finally released.

Co-Diagnostics announced on Tuesday that it has been awarded two grants from the Bill and Melinda Gates Foundation totaling $2.3 million for its tuberculosis and human papillomavirus tests.

QIAGEN announced today the expansion of its digital PCR (dPCR) offering for the development of cell and gene therapies in the biopharma industry.

Molecular diagnosis refers to the technique of using molecular biological methods to detect changes in the structure or expression level of genetic material in patients to make a diagnosis.

Devyser’s novel test for detecting donor-derived cell-free DNA in blood samples from kidney-transplant patients and its product for screening and follow-up of stem cell transplant patients fulfill IVDR requirements in Europe.

Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced a new partnership combining their respective immunoassay strengths to support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in the field of neurodegenerative diseases.

On the evening of July 12, Zhejiang Orient Gene Biotech Co., Ltd announced that its wholly owned subsidiary, Shanghai Wanzi Health Medical Laboratory Co., Ltd., had obtained medical device registration certificates for carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragment detection kit (flow fluorescence luminescence method).

A partnership between Quest Diagnostics and Envision Sciences has introduced a new prostate cancer biomarker test.